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Influenza sIRs with Minimal 
pneumonitis
Shruti Erramilli1, Praveen Mannam1* and Constantine A. Manthous2
1 Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine,  
New Haven, CT, USA, 2 Lawrence and Memorial Hospital, New London, CT, USA
Although systemic inflammatory response syndrome (SIRS) is a known complication of 
severe influenza pneumonia, it has been reported very rarely in patients with minimal 
parenchymal lung disease. We here report a case of severe SIRS, anasarca, and marked 
vascular phenomena with minimal or no pneumonitis. This case highlights that viruses, 
including influenza, may cause vascular dysregulation causing SIRS, even without sub-
stantial visceral organ involvement.
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INtRoDUCtIoN
Influenza viruses are among the most common respiratory tract infections in humans and are a 
common cause of morbidity and mortality (1). Although systemic inflammatory response syn-
drome (SIRS) has been described after influenza infection, nearly all reported cases had severe lung 
injury and/or bacterial infections (2, 3). Here, we describe an unusual presentation of influenza 
infection with severe SIRS and multiple organ dysfunctions but without parenchymal infiltrates or 
lung injury.
Case pReseNtatIoN
A 44-year-old female with a remote past medical history of Stage IIb breast cancer, treated with 
mastectomy, chemotherapy, and radiation, presented with complaints of non-productive cough, 
malaise, and lower extremity paresthesias of 1 week duration. On presentation, her vitals were BP 
110/62, heart rate 102, respiratory rate 18, and O2 saturations of 100% on room air (Figure 1). 
She was initially admitted to hospital wards, but became increasingly restless with leg pain, and 
developed hypotension with blood pressure of 80/50, leading to ICU transfer on the second 
hospital day. At the time of transfer, she was noted to be hypotensive with leukocytosis (WBC 
of 34.8 × 1000/μL), hemoconcentration (Hgb of 17.8 g/dL), thrombocytopenia (platelet count of 
70 × 1000/μL), hyponatremia (Na+ of 129 mmol/L), and lactic acidosis (5.3 mmol/L). Creatine 
kinase was 966 U/L, and renal function and electrolytes were normal. She was hypoalbuminemic 
(1.6  g/dL), and her procalcitonin was (low) 0.25 μg/L. She had an elevated troponin I levels, 
0.62 ng/mL (Ref range <0.06) and a normal EKG. Liver function tests showed mild elevation in 
AST 48 U/L (Ref range 15–37 U/L) and low alkaline phosphatase 37 U/L (Ref range 45–117 U/L). 
The bilirubin and AST levels were normal. Chest radiograph suggested a possible, subtle right 
lower lobe interstitial infiltrate (Figure  2). A rapid test nasal swab was positive for influenza 
B, and she was treated with oseltamivir and levofloxacin. Her hypotension became persistent 
and unresponsive (more than 7  L fluid administered on day of ICU transfer and 14  L over 
48  h) prompting addition of norepinephrine and phenylephrine titrated to a systolic blood 
FIGURe 1 | Graphical representation of sIRs criteria trends during ICU stay.
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pressure of 100  mmHg. Antibiotics were also broadened to 
include vancomycin and piperacillin/tazobactam. Computed 
tomography of chest, abdomen, and pelvis demonstrated 
anasarca with bilateral pleural effusions, mild peri-effusion 
compressive atelectasis, and ascites. Lung parenchyma was 
otherwise clear (Figure  2). Her most remarkable complaint 
was severe lower extremity pain/paresthesias associated with 
profound (gray/purple) mottling. Screening for disseminated 
intravascular coagulation showed a prothrombin time 13.8  s 
(Ref range 9.6–11.6 s), partial thromboplastin time 42.8 s (Ref 
range 21.9–31.4  s), and fibrinogen 205.2  mg/dL (Ref range 
217–425 mg/dL) but normal d-dimer. The ISTH DIC score was 
4 suggesting absence of DIC. Lupus anticoagulants 1 and 2 were 
slightly above normal (50 and 36 s, upper limits 42 and 35 s). 
Ultrasounds of her extremities did not demonstrate thrombosis. 
Gram stain and cultures of blood, sputum, and urine showed 
no bacterial pathogens, and procalcitonin levels remained low 
on multiple serial tests. The coagulopathy reversed and she 
was weaned off vasopressors on day 3. She never developed 
respiratory failure, requiring modest supplemental oxygen of 
2 L O2 throughout, and discharged from ICU on day 5.
DIsCUssIoN
Although there are many reports of SIRS associated with influ-
enza, few if any cases have been described without primary lung 
involvement, i.e., influenza pneumonia/ARDS. While cases of 
primary influenza SIRS without pneumonia may be embedded 
in case series (4–6), we could find only two cases of influenza 
SIRS, explicitly described to have no pneumonia (7, 8).
The primary clinical manifestations of influenza infection 
are in the lung. The primary portal entry of influenza is the 
aero-digestive tract, specifically the respiratory epithelium. 
Epithelial infection causes upper respiratory infection, which 
may spread distally to cause tracheobronchitis. When small 
airways/airspaces become infected, in the most severe cases, it 
may cause distal inflammation, pulmonary edema, and ARDS. 
This may occur, in part, by impairing edema fluid clearance by 
inhibiting epithelial Na channel (ENaC) (9, 10). Influenza also 
stimulates inflammatory cells such as lung macrophages, neutro-
phils, and T cells that may contribute to “cytokine storm,” which 
may promote lung injury and SIRS (11, 12). Recent studies have 
demonstrated that endothelial cells play an important role in the 
pathogenesis of SIRS associated with influenza infection (13). 
Mechanisms of endothelial injury include cytokine-mediated 
disruption of cell–cell junctions. Activated endothelial cells may 
express adhesion molecules that recruit inflammatory cells such a 
neutrophils leading to further injury (14, 15). Influenza may also 
directly infect endothelial cells with activation of NF-κB causing 
apoptosis (16).
Our patient presented with non-productive cough and 
no interstitial parenchymal infiltrates on CT scan. She never 
developed severe pneumonia or ARDS, whereas influenza 
B manifested mainly as severe SIRS. We thus speculate that 
cytokine storm and endothelial dysfunction may have been the 
primary pathogenic mechanism of her illness. The presence 
of small vessel clinical signs (profound skin mottling), diffuse 
capillary leak (with large effusions, ascites, and anasarca), 
coagulation abnormalities, and lupus anticoagulant during 
our patient’s illness support this hypothesis. She developed 
FIGURe 2 | (a) Initial chest radiograph. (B) Chest radiograph 48 h at ICU admission. (C) Corresponding CT chest with representative cuts at bases (just above 
diaphragm) and upper-chest showing large pleural effusions and some adjacent compressive atelectasis but little/no parenchymal infiltrate.
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no signs of macro-vascular thrombosis. Lupus anticoagula-
tion has been reported to interact with the endothelium and 
impairs prostacyclin release to induce thrombosis (17–19). 
Our patient’s course is consistent with a growing literature 
describing endothelial dysfunction in viral infections (20). 
Evidence suggests that treatment with neuraminidase inhibi-
tors reduces severe clinical outcomes in patients hospitalized 
with influenza. A review of the hospitalized patients with 
H1NI infection 2009–2010 showed that administration of 
neuraminidase inhibitors was associated with a reduction 
in mortality risk [adjusted odds ratio (OR) 0.81; 95% CI 
0.70–0.93; p = 0.0024]. Although early initiation of treatment 
is advocated, there appears to be a benefit even among those 
starting treatment up to 5 days after symptom onset (21, 22). 
The side effects associated with treatment are typically mild 
such as transient upper respiratory and gastrointestinal 
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symptoms (23). At present, there are no specific therapies to 
treat the extensive endothelial damage associated with infec-
tion except for supportive care.
It is possible that our patient had an occult, unidentified 
bacterial infection that responded to antibacterial therapy. 
Nonetheless, the weight of evidence, including a CT scan of 
chest, abdomen, pelvis without parenchymal infiltrates or any 
other source, negative cultures, no localizing signs of alternate 
infection, and low procalcitonin levels, suggests that our patient 
had only influenza infection. We believe this case highlights the 
growing appreciation that viruses can cause SIRS, and in the 
case of influenza, this may occur in the absence of pneumonia 
or severe lung injury.
The patient provided informed consent and IRB approval 
was not required by the institution for publication of the case 
report.
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